BR9602628A - Composto composição farmacêutica método para o tratamento de uma condição e método para diminuir a secreção de apo b num mamífero - Google Patents
Composto composição farmacêutica método para o tratamento de uma condição e método para diminuir a secreção de apo b num mamíferoInfo
- Publication number
- BR9602628A BR9602628A BR9602628A BR9602628A BR9602628A BR 9602628 A BR9602628 A BR 9602628A BR 9602628 A BR9602628 A BR 9602628A BR 9602628 A BR9602628 A BR 9602628A BR 9602628 A BR9602628 A BR 9602628A
- Authority
- BR
- Brazil
- Prior art keywords
- secretion
- mammal
- treating
- condition
- pharmaceutical composition
- Prior art date
Links
- 241000124008 Mammalia Species 0.000 title 1
- 150000001875 compounds Chemical class 0.000 title 1
- 230000003247 decreasing effect Effects 0.000 title 1
- 239000008194 pharmaceutical composition Substances 0.000 title 1
- 230000028327 secretion Effects 0.000 title 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D217/00—Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems
- C07D217/02—Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems with only hydrogen atoms or radicals containing only carbon and hydrogen atoms, directly attached to carbon atoms of the nitrogen-containing ring; Alkylene-bis-isoquinolines
- C07D217/04—Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems with only hydrogen atoms or radicals containing only carbon and hydrogen atoms, directly attached to carbon atoms of the nitrogen-containing ring; Alkylene-bis-isoquinolines with hydrocarbon or substituted hydrocarbon radicals attached to the ring nitrogen atom
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D217/00—Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems
- C07D217/02—Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems with only hydrogen atoms or radicals containing only carbon and hydrogen atoms, directly attached to carbon atoms of the nitrogen-containing ring; Alkylene-bis-isoquinolines
- C07D217/06—Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems with only hydrogen atoms or radicals containing only carbon and hydrogen atoms, directly attached to carbon atoms of the nitrogen-containing ring; Alkylene-bis-isoquinolines with the ring nitrogen atom acylated by carboxylic or carbonic acids, or with sulfur or nitrogen analogues thereof, e.g. carbamates
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/10—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing aromatic rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
- C07D405/06—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
- C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
- C07D409/06—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
- C07D413/06—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
- C07D417/06—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
Landscapes
- Organic Chemistry (AREA)
- Chemical & Material Sciences (AREA)
- Health & Medical Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- General Health & Medical Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Heart & Thoracic Surgery (AREA)
- Diabetes (AREA)
- Cardiology (AREA)
- Vascular Medicine (AREA)
- Urology & Nephrology (AREA)
- Endocrinology (AREA)
- Hematology (AREA)
- Obesity (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CA002223574A CA2223574C (en) | 1995-06-07 | 1995-06-07 | Biphenyl-2-carboxylic acid-tetrahydro-isoquinolin-6-yl amide derivatives, their preparation and their use as inhibitors of microsomal triglyceride transfer protein and/or apolipoprotein b (apo b) secretion |
| PCT/IB1995/000448 WO1996040640A1 (en) | 1995-06-07 | 1995-06-07 | BIPHENYL-2-CARBOXYLIC ACID-TETRAHYDRO-ISOQUINOLIN-6-YL AMIDE DERIVATIVES, THEIR PREPARATION AND THEIR USE AS INHIBITORS OF MICROSOMAL TRIGLYCERIDE TRANSFER PROTEIN AND/OR APOLIPOPROTEIN B (Apo B) SECRETION |
| HU9601566A HUP9601566A3 (en) | 1995-06-07 | 1996-06-06 | Therapeutic tetrahydro-isoquinolin derivatives, their intermediates and pharmaceutical compositions containing the active component |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| BR9602628A true BR9602628A (pt) | 1998-09-08 |
Family
ID=89994037
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| BR9602628A BR9602628A (pt) | 1995-06-07 | 1996-06-04 | Composto composição farmacêutica método para o tratamento de uma condição e método para diminuir a secreção de apo b num mamífero |
Country Status (14)
| Country | Link |
|---|---|
| EP (1) | EP0832069B1 (pt) |
| AP (1) | AP9600804A0 (pt) |
| BR (1) | BR9602628A (pt) |
| CZ (1) | CZ289249B6 (pt) |
| FI (1) | FI974440A (pt) |
| HR (1) | HRP960270A2 (pt) |
| HU (1) | HUP9601566A3 (pt) |
| IL (1) | IL118484A (pt) |
| LV (1) | LV11615B (pt) |
| NZ (1) | NZ286733A (pt) |
| PL (1) | PL314636A1 (pt) |
| SG (1) | SG44952A1 (pt) |
| SI (1) | SI9600183A (pt) |
| WO (1) | WO1996040640A1 (pt) |
Families Citing this family (60)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5739135A (en) * | 1993-09-03 | 1998-04-14 | Bristol-Myers Squibb Company | Inhibitors of microsomal triglyceride transfer protein and method |
| ATE264833T1 (de) * | 1996-01-16 | 2004-05-15 | Bristol Myers Squibb Co | Konformationseingeschränkte aromatische inhibitoren des microsomalen triglyceridtransferproteins und verfahren |
| DK0902785T3 (da) * | 1996-04-30 | 2002-10-07 | Pfizer | Fremgangsmåder og mellemprodukter til fremstilling af 4'-trifluormethylbiphenyl-2-carboxylsyre-[2-(2H-[1,2,4]triazol-3-ylmethyl)-1,2,3,4-tetrahydroisoquinolin-2-yl]amid |
| US5885983A (en) * | 1996-05-10 | 1999-03-23 | Bristol-Myers Squibb Company | Inhibitors of microsomal triglyceride transfer protein and method |
| US5827875A (en) * | 1996-05-10 | 1998-10-27 | Bristol-Myers Squibb Company | Inhibitors of microsomal triglyceride transfer protein and method |
| TW438796B (en) * | 1996-05-15 | 2001-06-07 | Hoffmann La Roche | 2,4-diaminopyrimidine derivatives, the manufacture process thereof, and the antibiotically-active pharmaceutical composition containing the same |
| US5883109A (en) * | 1996-07-24 | 1999-03-16 | Bristol-Myers Squibb Company | Method for lowering serum lipid levels employing an MTP inhibitor in combination with another cholesterol lowering drug |
| AU716151B2 (en) * | 1996-11-27 | 2000-02-17 | Pfizer Inc. | Apo B-secretion/MTP inhibitory amides |
| US5760246A (en) * | 1996-12-17 | 1998-06-02 | Biller; Scott A. | Conformationally restricted aromatic inhibitors of microsomal triglyceride transfer protein and method |
| KR20010006479A (ko) * | 1997-04-18 | 2001-01-26 | 디. 제이. 우드 | 4'-트리플루오로메틸-비페닐-2-카르복실산 (1,2,3,4-테트라히드로-이소퀴놀린-6-일)아미드의 제법 및 제조 중간체 |
| GB9708119D0 (en) * | 1997-04-22 | 1997-06-11 | Glaxo Group Ltd | Chemical compounds |
| US5968950A (en) * | 1997-06-23 | 1999-10-19 | Pfizer Inc | Apo B-secretion/MTP inhibitor hydrochloride salt |
| WO1999063929A2 (en) | 1998-06-08 | 1999-12-16 | Advanced Medicine, Inc. | Multibinding inhibitors of microsomal triglyceride transferase protein |
| US6197798B1 (en) | 1998-07-21 | 2001-03-06 | Novartis Ag | Amino-benzocycloalkane derivatives |
| CO5090829A1 (es) * | 1998-07-21 | 2001-10-30 | Novartis Ag | Compuestos organicos de la formula i, utiles como inhibido res de la proteina de transferencia de triglicerido microso mal y de la secrecion de la apolipoproteina b. |
| GB9826412D0 (en) * | 1998-12-03 | 1999-01-27 | Glaxo Group Ltd | Chemical compounds |
| AU6824700A (en) * | 1999-07-20 | 2001-02-05 | Novartis Ag | Organic compounds |
| CA2324801A1 (en) * | 1999-11-10 | 2001-05-10 | Andrew Gordon Swick | Use of apo b secretion/mtp inhibitors and anti-obesity agents |
| IL139450A0 (en) * | 1999-11-10 | 2001-11-25 | Pfizer Prod Inc | Methods of administering apo b-secretion/mtp inhibitors |
| CO5271688A1 (es) * | 1999-11-10 | 2003-04-30 | Pfizer Prod Inc | Uso de inhibidor de secrecion de apoliproteinas b y/o de proteina de transferencia de trigliceridos microsmales |
| CA2324800A1 (en) * | 1999-11-10 | 2001-05-10 | Mary Anne Hickman | Use of apo b secretion/mtp inhibitors |
| WO2001077077A1 (en) * | 2000-04-10 | 2001-10-18 | Novartis Ag | Substituted (hetero)aryl carboxamide derivatives as microsomal triglyceride transfer protein (mtp) and apolipoprotein b (apo b) secretion |
| GB0013383D0 (en) * | 2000-06-01 | 2000-07-26 | Glaxo Group Ltd | Therapeutic benzamide derivatives |
| GB0013346D0 (en) * | 2000-06-01 | 2000-07-26 | Glaxo Group Ltd | Therapeutic benzamide derivatives |
| DE10033337A1 (de) * | 2000-07-08 | 2002-01-17 | Boehringer Ingelheim Pharma | Biphenylcarbonsäureamide, ihre Herstellung und ihre Verwendung als Arzneimittel |
| AU2001277728A1 (en) * | 2000-08-10 | 2002-02-25 | Tanabe Seiyaku Co., Ltd. | Biphenylcarboxamidoisoindoline compounds, processes for the preparation of the same and intermediates for the synthesis thereof |
| AU2001277727A1 (en) * | 2000-08-10 | 2002-02-25 | Tanabe Seiyaku Co., Ltd. | Benzoylaminoisoindoline compounds, processes for the preparation of the same andintermediates for the synthesis thereof |
| JO2654B1 (en) | 2000-09-04 | 2012-06-17 | شركة جانسين فارماسوتيكا ان. في | Multiple aryl caroxa amides are useful as lipid - lowering agents |
| KR20030067675A (ko) * | 2000-10-05 | 2003-08-14 | 후지사와 야꾸힝 고교 가부시키가이샤 | 벤자미드 화합물 |
| JO2409B1 (en) | 2000-11-21 | 2007-06-17 | شركة جانسين فارماسوتيكا ان. في | Second-phenyl carboxy amides are useful as lipid-lowering agents |
| JO2390B1 (en) | 2001-04-06 | 2007-06-17 | شركة جانسين فارماسوتيكا ان. في | Diphenylcarboxamides act as lipid-lowering agents |
| WO2002090347A1 (en) * | 2001-04-30 | 2002-11-14 | Fujisawa Pharmaceutical Co., Ltd. | Amide compounds |
| EP1404653B1 (en) * | 2001-06-28 | 2008-08-20 | Pfizer Products Inc. | Triamide-substituted indoles, benzofuranes and benzothiophenes as inhibitors of microsomal triglyceride transfer protein (mtp) and/or apolipoprotein b (apo b) secretion |
| AU2002344567A1 (en) * | 2001-11-28 | 2003-06-10 | Daiso Co., Ltd. | Heterocyclic amide compounds as apolipoprotein b inhibitors |
| GB0129015D0 (en) * | 2001-12-04 | 2002-01-23 | Glaxo Group Ltd | Compounds |
| GB0129013D0 (en) * | 2001-12-04 | 2002-01-23 | Glaxo Group Ltd | Compounds |
| TW200403223A (en) | 2002-02-15 | 2004-03-01 | Glaxo Group Ltd | Novel compounds |
| BR0306292A (pt) | 2002-02-28 | 2004-08-24 | Japan Tobacco Inc | Composto de éster e uso medicinal do mesmo |
| WO2004039795A2 (en) * | 2002-10-29 | 2004-05-13 | Fujisawa Pharmaceutical Co., Ltd. | Amide compounds for the treatment of hyperlipidemia |
| EP1653968A4 (en) | 2003-07-23 | 2006-09-06 | Synta Pharmaceuticals Corp | METHOD FOR MODULATING CALCIUMION RELIEF ACTIVATED CALCIUMION CHANNELS |
| WO2005021486A1 (ja) | 2003-08-29 | 2005-03-10 | Japan Tobacco Inc. | エステル誘導体及びその医薬用途 |
| GB2413129A (en) * | 2003-10-07 | 2005-10-19 | Renovis Inc | Aromatic amide compounds as ion channel ligands and uses thereof |
| MXPA06003949A (es) | 2003-10-07 | 2006-06-27 | Renovis Inc | Compuestos amida como ligandos del canal de ion y su uso. |
| KR100799802B1 (ko) | 2004-02-04 | 2008-01-31 | 화이자 프로덕츠 인크. | 치환된 퀴놀린 화합물 |
| SI1725234T2 (sl) | 2004-03-05 | 2016-05-31 | The Trustees Of The University Of Pennsylvania | Postopki zdravljenja nepravilnosti ali bolezni povezanih s hiperlipidemijo in hiperholesterolemijo z minimiziranjem stranskih učinkov |
| US8101774B2 (en) | 2004-10-18 | 2012-01-24 | Japan Tobacco Inc. | Ester derivatives and medicinal use thereof |
| JP2006249022A (ja) | 2005-03-11 | 2006-09-21 | Sumitomo Chemical Co Ltd | ４−（２−メチルフェニル）ベンゾトリフルオライドの製造方法 |
| CA2605510C (en) | 2005-04-19 | 2013-12-24 | Surface Logix, Inc. | Inhibitors of microsomal triglyceride transfer protein and apo-b secretion |
| US7741317B2 (en) | 2005-10-21 | 2010-06-22 | Bristol-Myers Squibb Company | LXR modulators |
| US7888376B2 (en) | 2005-11-23 | 2011-02-15 | Bristol-Myers Squibb Company | Heterocyclic CETP inhibitors |
| DE102005062987A1 (de) * | 2005-12-28 | 2007-07-05 | Grünenthal GmbH | Substituierte Propiolsäureamide und ihre Verwendung zur Herstellung von Arzneimitteln |
| US7919506B2 (en) | 2006-03-10 | 2011-04-05 | Pfizer Inc. | Dibenzyl amine compounds and derivatives |
| US8383660B2 (en) | 2006-03-10 | 2013-02-26 | Pfizer Inc. | Dibenzyl amine compounds and derivatives |
| WO2008015416A1 (en) | 2006-08-01 | 2008-02-07 | Glaxo Group Limited | Pyrazolo[3,4-b]pyridine compounds, and their use as pde4 inhibitors |
| JO2653B1 (en) * | 2006-10-24 | 2012-06-17 | شركة جانسين فارماسوتيكا ان. في | Tetrahydroflavin 1-carboxylic acid substituted with pyridine or pyrazine inhibit MTB |
| AU2007310927B2 (en) | 2006-10-24 | 2012-01-12 | Janssen Pharmaceutica Nv | MTP inhibiting tetrahydro-naphthalene-1-carboxylic acid derivatives |
| ES2382009T3 (es) | 2006-12-01 | 2012-06-04 | Bristol-Myers Squibb Company | Derivados de N-((3-bencil)-2,2-(bis-fenil-)-propan-1-amina como inhibidores de CETP para el tratamiento de aterosclerosis y enfermedades cardiovasculares |
| AU2014255381A1 (en) | 2013-04-17 | 2015-10-08 | Pfizer Inc. | N-piperidin-3-ylbenzamide derivatives for treating cardiovascular diseases |
| WO2016055901A1 (en) | 2014-10-08 | 2016-04-14 | Pfizer Inc. | Substituted amide compounds |
| EP3911648A4 (en) | 2019-01-18 | 2022-10-26 | Astrazeneca AB | PCSK9 INHIBITORS AND METHODS OF USE THEREOF |
Family Cites Families (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4022900A (en) * | 1970-09-09 | 1977-05-10 | Marion Laboratories, Inc. | Compositions containing 1,2,3,4-tetrahydroisoquinolines used as hypotensive agents |
| DK410183A (da) * | 1982-09-10 | 1984-03-11 | Wellcome Found | 2-(substitueret-phenyl)-benzoesyrederivater, fremgangsmaade til deres fremstilling samt deres anvendelse |
| US5595872A (en) * | 1992-03-06 | 1997-01-21 | Bristol-Myers Squibb Company | Nucleic acids encoding microsomal trigyceride transfer protein |
| IL110172A (en) * | 1993-07-22 | 2001-10-31 | Lilly Co Eli | Bicycle compounds and pharmaceuticals containing them |
-
1995
- 1995-06-07 WO PCT/IB1995/000448 patent/WO1996040640A1/en active IP Right Grant
- 1995-06-07 EP EP95918722A patent/EP0832069B1/en not_active Expired - Lifetime
-
1996
- 1996-05-09 AP APAP/P/1996/000804A patent/AP9600804A0/en unknown
- 1996-05-30 IL IL11848496A patent/IL118484A/en not_active IP Right Cessation
- 1996-06-04 BR BR9602628A patent/BR9602628A/pt not_active Application Discontinuation
- 1996-06-05 NZ NZ286733A patent/NZ286733A/en unknown
- 1996-06-05 SG SG1996009974A patent/SG44952A1/en unknown
- 1996-06-05 PL PL96314636A patent/PL314636A1/xx unknown
- 1996-06-06 LV LVP-96-176A patent/LV11615B/en unknown
- 1996-06-06 CZ CZ19961644A patent/CZ289249B6/cs not_active IP Right Cessation
- 1996-06-06 HR HRPCT/IB95/00448A patent/HRP960270A2/hr not_active Application Discontinuation
- 1996-06-06 SI SI9600183A patent/SI9600183A/sl not_active IP Right Cessation
- 1996-06-06 HU HU9601566A patent/HUP9601566A3/hu unknown
-
1997
- 1997-12-05 FI FI974440A patent/FI974440A/fi not_active Application Discontinuation
Also Published As
| Publication number | Publication date |
|---|---|
| EP0832069B1 (en) | 2003-03-05 |
| IL118484A (en) | 2001-11-25 |
| PL314636A1 (en) | 1996-12-09 |
| IL118484A0 (en) | 1996-09-12 |
| WO1996040640A1 (en) | 1996-12-19 |
| NZ286733A (en) | 1998-02-26 |
| AP9600804A0 (en) | 1997-11-09 |
| HUP9601566A3 (en) | 1998-01-28 |
| CZ164496A3 (en) | 1997-01-15 |
| FI974440A (fi) | 1998-01-27 |
| HRP960270A2 (en) | 1997-12-31 |
| FI974440A0 (fi) | 1997-12-05 |
| CZ289249B6 (cs) | 2001-12-12 |
| LV11615A (lv) | 1996-12-20 |
| EP0832069A1 (en) | 1998-04-01 |
| HUP9601566A2 (en) | 1997-09-29 |
| LV11615B (en) | 1997-04-20 |
| SI9600183A (en) | 1997-04-30 |
| SG44952A1 (en) | 1997-12-19 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| BR9602628A (pt) | Composto composição farmacêutica método para o tratamento de uma condição e método para diminuir a secreção de apo b num mamífero | |
| BR9606575A (pt) | Composição incapacitante e dispositivo para o emprego de uma composição incapacitante | |
| FI962445A0 (fi) | Paroksetiinitabletteja ja menetelmä niiden valmistamiseksi | |
| BR9508586A (pt) | Compostos processo de preparação dos mesmos uso dos mesmos processo de tratamento de uma condição clínica em um mamífero e composição farmacêutica | |
| FI965093A (fi) | Laite ja menetelmä kellon säätämiseksi ja kytkemiseksi | |
| EP0583665A3 (en) | Pharmaceutical composition and method for treating hyperlipidemia and arteriosclerosis | |
| AU2265095A (en) | Method and composition for treating renal disease and failure | |
| BR9504385A (pt) | Composto composiçao farmaceutica metodos para a inibiçao de ligaçao e para o tratamento de dersordens inflamatorias | |
| AU2027695A (en) | Pharmaceutical composition for treating stoma-peripheral inflammation diseases | |
| IS4466A (is) | Samsetning og meðhöndlun fyrir heila- og mænusigg | |
| BR9607095A (pt) | Composto composição farmacêutica e processos para fabricar e para administrar um composto | |
| BR9407265A (pt) | Composto composições farmacêuticas e métodos para tratamento de câncer em um mamifero | |
| BR9505995A (pt) | Composto método para tratamentos e composição farmacêutica | |
| ITMI950665A0 (it) | Componente multistrato | |
| EE9800164A (et) | Farmatseutiline kompositsioon ja meetod epitelioomi raviks | |
| BR9507872A (pt) | Método e composição para aumentar a absorção de cálcio | |
| BR9105821A (pt) | Processo para a ajustagem de uma valvula e valvula | |
| BR9507768A (pt) | Composição farmacêutica | |
| FI942298A0 (fi) | Menetelmä ja sovitelma tilaelementtien siirtämiseksi | |
| FI955123A (fi) | Kolestyramiinia sisältävä koostumus ja menetelmä tämän valmistamiseksi | |
| BR9611383A (pt) | Peptídeo composição farmacêutica e processos para tratar um tumor em um mamífero e preparar os compostos | |
| BR9704832A (pt) | Composição anti-formação de domo para uma máscara de sombra e processo para sua preparação | |
| BR9710544A (pt) | M-todo de tratamento composto e composi-Æo farmac-utica | |
| AU4137596A (en) | Method for the treatment of periodontal disease and a pharmaceutical composition useful in said method | |
| BR9504119A (pt) | Composto composiçao farmacêutica métodos para tratar uma infecçao bacteriana e uma infecçao micoplásmica |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FB34 | Technical and formal requirements: requirement - article 34 of industrial property law | ||
| B07A | Application suspended after technical examination (opinion) [chapter 7.1 patent gazette] | ||
| B06A | Patent application procedure suspended [chapter 6.1 patent gazette] | ||
| B11B | Dismissal acc. art. 36, par 1 of ipl - no reply within 90 days to fullfil the necessary requirements |